Gabapentin Capsule
Product Images NDC 50090-4893

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-4893). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula panel showing the calculation for creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor adjusting for female patients. The formula is represented mathematically, indicating how to compute CLCr using these patient variables.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain score over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score ranging from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains nearly constant.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain score over a 7-week period. The x-axis represents weeks including a baseline and two study periods: a 3-week dose titration and a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. Three lines compare placebo and Gabapentin dosed at 1800 mg/day and 2400 mg/day, illustrating pain score changes over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. It compares placebo (PBO) and gabapentin (GBP) at different doses (3600 mg for Study 1; 1800 mg and 2400 mg for Study 2). Percentages of responders are indicated above each bar, with statistical significance noted (p < 0.01, p < 0.001).*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart showing the percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis. The chart compares data points labeled as Study a, Study b, and Study c, each represented by different colored squares, illustrating differences in percentage across various daily doses ranging from approximately 600 mg to 1800 mg.*

FDA Label Image

Gabapentin-struc (Gabapentin Struc)

Chemical structure of gabapentin showing a cyclohexane ring with an amino (CH2NH2) and a carboxyl (CH2CO2H) side chain attached.*

FDA Label Image

Label Image (Lbl500904893)

Gabapentin 300 mg oral capsules packaging label from A-S Medication Solutions. The label specifies 90 capsules per container, with each capsule containing 300 mg of gabapentin. Storage instructions indicate to keep the product between 68 to 77 degrees Fahrenheit. The label includes the NDC 50090-4893 and a QR code for dosage and package insert information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.